Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Product sales, net	$ 1,648,368	$ 2,425,738	$ 4,349,270	$ 5,350,445
Cost of products sold	967,720	1,056,384	1,986,196	2,178,797
Gross profit	680,648	1,369,354	2,363,074	3,171,648
Selling, general and administrative expenses	3,282,322	4,011,672	6,397,948	6,760,969
Research and development expenses	266,560	215,420	731,027	231,864
Depreciation and amortization expense	16,645	14,834	33,460	35,760
Total operating expenses	3,565,527	4,241,926	7,162,435	7,028,593
Loss from operations	(2,884,879)	(2,872,572)	(4,799,361)	(3,856,945)
Interest income (expense)	3,550	(4,461)	(1,193)	(6,996)
Gain on debt extinguishment-PPP	0	276,180	0	276,180
Loss before provision for income taxes and equity investments	(2,881,329)	(2,600,853)	(4,800,554)	(3,587,761)
Provision for income taxes	0	(83)	0	(333)
Loss before equity investment	(2,881,329)	(2,600,936)	(4,800,554)	(3,588,094)
Deferred profit and divesture-equity investment (See Note 6)	0	(95,857)	0	(94,556)
Net loss	(2,881,329)	(2,696,793)	(4,800,554)	(3,682,650)
Net loss attributable to noncontrolling interests	(22,848)	(16,325)	(40,350)	(29,313)
Net loss attributable to Milestone Scientific Inc.	$ (2,858,481)	$ (2,680,468)	$ (4,760,204)	$ (3,653,337)
Net loss per share applicable to common stockholders—
Basic (in dollars per share)	$ (0.04)	$ (0.04)	$ (0.07)	$ (0.05)
Diluted (in dollars per share)	$ (0.04)	$ (0.04)	$ (0.07)	$ (0.05)
Weighted average shares outstanding and to be issued—
Basic (in shares)	70,356,796	69,220,795	70,585,590	68,286,033
Diluted (in shares)	70,356,796	69,220,795	70,585,590	68,286,033